Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3325558 | 1.00 | FEN1 (0.46) | FEN1HTR1ASLC6A2SCN9AIKBKB | |
| SCHEMBL3326057 | 0.87 | SLC6A2 (0.46) | FEN1HTR1ASLC6A2SCN9AIKBKB | |
| SCHEMBL3326063 | 0.87 | SLC6A2 (0.46) | FEN1HTR1ASLC6A2SCN9AIKBKB | |
| SCHEMBL3321594 | 0.86 | HTR1A (0.47) | FEN1HTR1ASLC6A2SCN9AIKBKB | |
| SCHEMBL3325185 | 0.86 | HTR1A (0.47) | FEN1HTR1ASLC6A2SCN9AIKBKB | |
| SCHEMBL3325164 | 0.84 | IKBKB (0.47) | HTR1ASLC6A2SCN9AIKBKBIRAK4 | |
| Hydrochloric Acid SCHEMBL3324980 | 0.83 | IKBKB (0.46) | HTR1ASLC6A2IKBKBIRAK4ALOX15 | |
| SCHEMBL3325416 | 0.81 | SLC6A2 (0.50) | FEN1HTR1ASLC6A2IKBKB | |
| SCHEMBL3328235 | 0.81 | SLC6A2 (0.50) | FEN1HTR1ASLC6A2IKBKB | |
| SCHEMBL27751579 | 0.78 | SCN9A (0.45) | FEN1HTR1ASLC6A2SCN9AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | PFIZER INC. | 2010-05-13 | — | — | US | disclosed |
| CN-101506164-A | Piperidine derivatives | PFIZER PROD INC (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-2066630-A1 | PIPERIDINE DERIVATIVES | Pfizer Products Incorporated (US) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008023258-A1 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120858-A1 | Piperidine Derivatives | P2RX5, P2RX7, P2RX1 | FEN1 4514/4885HTR1A 302/4885SLC6A2 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.